ATC
PBE icon

Adirondack Trust Company’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Adirondack Trust Company’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-47
Closed -$3.04K – 502
2024
Q1 		$3.04K Hold
47
– – ﹤0.01% 446
2023
Q4 		$3.08K Sell
47
-602
-93% -$35K ﹤0.01% 441
2023
Q3 		$37K Hold
649
– – 0.02% 246
2023
Q2 		$41.2K Sell
649
-51
-7% -$3.18K 0.02% 222
2023
Q1 		$43.9K Hold
700
– – 0.02% 212
2022
Q4 		$44.4K Hold
700
– – 0.02% 211
2022
Q3 		$41K Buy
+700
New +$43.1K 0.02% 209

Other funds holding PBE

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
CW
CreativeOne Wealth Overland Park, Kansas $4.31B AUM 19.42% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
OCM
One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Adirondack Trust Company's PBE Position: Q2 2024 in Review

Adirondack Trust Company sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2024, closing a stake of 47 shares — an estimated $3.04K sold.

Adirondack Trust Company first reported a position in PBE in Q3 2022 and held it in 7 quarters. The position peaked at $44.4K in Q4 2022. 100 funds tracked by Wall St. Rank hold PBE as of Q2 2024.

  • Adirondack Trust Company reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2024 after selling out during the quarter.
  • Adirondack Trust Company sold 47 Invesco Biotechnology & Genome ETF shares in Q2 2024, an estimated $3.04K.
  • Adirondack Trust Company first reported a position in Invesco Biotechnology & Genome ETF in Q3 2022 and held it in 7 quarters.
  • Adirondack Trust Company's Invesco Biotechnology & Genome ETF position peaked at $44.4K in Q4 2022.
  • 100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2024.

Based on Adirondack Trust Company's 13F filing for Q2 2024, filed 9 Jul 2024.